St. Jude Medical Reports Data From EnligHTN III Study; Shows Continued Efficacy

(RTTNews) - St. Jude Medical, Inc. (STJ) announced 12-month outcome data from the EnligHTN III study, which demonstrated a continuation of safe, rapid and effective treatment with the next-generation EnligHTN Renal Denervation System for patients with drug-resistant, uncontrolled hypertension.

The EnligHTN III study is an international, non-randomized clinical trial that followed device performance and assessed outcomes at six centers through twelve months of follow-up for 37 eligible patients. The EnligHTN III study expands upon the research conducted in the EnligHTN I trial of the first-generation EnligHTN system, which demonstrated that patients with drug-resistant hypertension had a safe drop in blood pressure.

The company said the twelve-month EnligHTN III data showed: an average office systolic blood pressure reduction of 23 mmHg points; an average ambulatory systolic blood pressure reduction of 10 mmHg points; 78 percent of patients responded to the therapy, which is defined as a blood pressure reduction of at least 10 mmHg when measured during an office visit.